ViaDerma Inc (VDRM)

[ORCA]

ViaDerma Inc. and its Subsidiary
Notes to Unaudited Consolidated Financial Statements
December 31, 2023
Management believes that the current available resources will not be sufficient to fund the Company’s planned
expenditures over the next 12 months. Accordingly, the Company will be dependent upon the raising of additional
capital through placement of common shares, and/or debt financing in order to implement its business plan and
generating sufficient revenue in excess of costs. If the Company raises additional capital through the issuance of
equity securities or securities convertible into equity, stockholders will experience dilution, and such securities may
have rights, preferences or privileges senior to those of the holders of common stock or convertible senior notes. If
the Company raises additional funds by issuing debt, the Company may be subject to limitations on its operations,
through debt covenants or other restrictions. If the Company obtains additional funds through arrangements with
collaborators or strategic partners, the Company may be required to relinquish its rights to certain geographical areas,
or techniques that it might otherwise seek to retain. There is no assurance that the Company will be successful with
future financing ventures, and the inability to secure such financing may have a material adverse effect on the
Company’s financial condition. These consolidated financial statements do not include any adjustments to the
amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue
as a going concern.